Biobetter jointly developed with Ildong, ‘ublituximab’ completed part 1 of Phase 2 clinical trial

Published: 2017-01-24 16:27:00
Updated: 2017-01-24 13:48:05

The development of ‘ublituximab(TG-1101),’ a TG Therapeutics’ monoclonal antibody biobetter, jointly conducted with Ildong Pharmaceutical(CEO Woong-Seup Yoon), passed the part 1 of the Phase 2 clinical trial in the U.S.

Ildong Pharmaceutical quoted the recent announcement of the original develop...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.